[Additional treatment with Esberitox N in patients with chemo-radiotherapy treatment of advanced breast cancer].

Abstract

A study was made at random on 70 female patients with advanced mamma carcinoma to find out whether an additional treatment with Esberitox N prevents or diminishes the sideeffects of a combined chemo-radiation therapy. As it could not be excluded that the efficacy of Esberitox N on previous affliction by haematotoxic therapy would probably differ, the study was made on various groups of risk. The parameter to form an opinion were either the peripheral hematosis or the appearance of infections. It turned out, however, that Esberitox N proved only effective if there was only a minor damage of the bonemarrow. The efficacy seems to promote the recuperation of the haemapoetic system. There was no significant frequency of infections by the additional Esberitox N treatment, yet in tendency favourably influenced.

• Authors: R Bendel, V Bendel, K Renner, V Carstens, K Stolze
• Journal: Onkologie (Onkologie) Vol. 12 Suppl 3 Pg. 32-8 (Jun 1989) ISSN: 0378-584X [Print] Switzerland
• Vernacular Title: Zusatzbehandlung mit Esberitox N bei Patientinnen mit chemo-strahlentherapeutischer Behandlung eines fortgeschrittenen Mammakarzinoms.
• PMID: 2481832 (Publication Type: Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial)

Chemical References

• Plant Extracts
• Esberitox

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Breast Neoplasms (drug therapy, radiotherapy, therapy)
• Combined Modality Therapy
• Female
• Follow-Up Studies
• Humans
• Middle Aged
• Neoplasm Metastasis
• Neoplasm Recurrence, Local (therapy)
• Palliative Care
• Plant Extracts (administration & dosage)
• Randomized Controlled Trials as Topic
• Risk Factors